Lethal Mutagenesis: Exploiting Error-Prone Replication of Riboviruses for Antiviral Therapy

Jason D. Graci, Craig Eugene Cameron

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Replication of RNA viruses is an errorâprone process leading to approximately one mutation per genome per replication. However, there is a maximum level of mutation, termed the error threshold, beyond which the error frequency is too great to support viability. This chapter examines the evidence supporting lethal mutagenesis in vitro and in vivo. Additionally, the impact of resistance and the challenges to development of clinically effective lethal mutagens are discussed.

Original languageEnglish (US)
Title of host publicationAntiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats
PublisherJohn Wiley and Sons
Pages203-220
Number of pages18
ISBN (Print)0471668273, 9780471668275
DOIs
StatePublished - Jan 27 2005

Fingerprint

Mutagenesis
Antiviral Agents
Mutagens
Viruses
Genes
RNA

All Science Journal Classification (ASJC) codes

  • Chemistry(all)

Cite this

Graci, J. D., & Cameron, C. E. (2005). Lethal Mutagenesis: Exploiting Error-Prone Replication of Riboviruses for Antiviral Therapy. In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats (pp. 203-220). John Wiley and Sons. https://doi.org/10.1002/0471716715.ch9
Graci, Jason D. ; Cameron, Craig Eugene. / Lethal Mutagenesis : Exploiting Error-Prone Replication of Riboviruses for Antiviral Therapy. Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats. John Wiley and Sons, 2005. pp. 203-220
@inbook{32b38e7d1c2e43d7a70263e37efc943b,
title = "Lethal Mutagenesis: Exploiting Error-Prone Replication of Riboviruses for Antiviral Therapy",
abstract = "Replication of RNA viruses is an error{\^a}prone process leading to approximately one mutation per genome per replication. However, there is a maximum level of mutation, termed the error threshold, beyond which the error frequency is too great to support viability. This chapter examines the evidence supporting lethal mutagenesis in vitro and in vivo. Additionally, the impact of resistance and the challenges to development of clinically effective lethal mutagens are discussed.",
author = "Graci, {Jason D.} and Cameron, {Craig Eugene}",
year = "2005",
month = "1",
day = "27",
doi = "10.1002/0471716715.ch9",
language = "English (US)",
isbn = "0471668273",
pages = "203--220",
booktitle = "Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats",
publisher = "John Wiley and Sons",

}

Graci, JD & Cameron, CE 2005, Lethal Mutagenesis: Exploiting Error-Prone Replication of Riboviruses for Antiviral Therapy. in Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats. John Wiley and Sons, pp. 203-220. https://doi.org/10.1002/0471716715.ch9

Lethal Mutagenesis : Exploiting Error-Prone Replication of Riboviruses for Antiviral Therapy. / Graci, Jason D.; Cameron, Craig Eugene.

Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats. John Wiley and Sons, 2005. p. 203-220.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Lethal Mutagenesis

T2 - Exploiting Error-Prone Replication of Riboviruses for Antiviral Therapy

AU - Graci, Jason D.

AU - Cameron, Craig Eugene

PY - 2005/1/27

Y1 - 2005/1/27

N2 - Replication of RNA viruses is an errorâprone process leading to approximately one mutation per genome per replication. However, there is a maximum level of mutation, termed the error threshold, beyond which the error frequency is too great to support viability. This chapter examines the evidence supporting lethal mutagenesis in vitro and in vivo. Additionally, the impact of resistance and the challenges to development of clinically effective lethal mutagens are discussed.

AB - Replication of RNA viruses is an errorâprone process leading to approximately one mutation per genome per replication. However, there is a maximum level of mutation, termed the error threshold, beyond which the error frequency is too great to support viability. This chapter examines the evidence supporting lethal mutagenesis in vitro and in vivo. Additionally, the impact of resistance and the challenges to development of clinically effective lethal mutagens are discussed.

UR - http://www.scopus.com/inward/record.url?scp=84891004035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891004035&partnerID=8YFLogxK

U2 - 10.1002/0471716715.ch9

DO - 10.1002/0471716715.ch9

M3 - Chapter

AN - SCOPUS:84891004035

SN - 0471668273

SN - 9780471668275

SP - 203

EP - 220

BT - Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats

PB - John Wiley and Sons

ER -

Graci JD, Cameron CE. Lethal Mutagenesis: Exploiting Error-Prone Replication of Riboviruses for Antiviral Therapy. In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats. John Wiley and Sons. 2005. p. 203-220 https://doi.org/10.1002/0471716715.ch9